U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

PubAg

Main content area

You searched for: Subject Infectious spleen and kidney necrosis virus Remove constraint Subject: Infectious spleen and kidney necrosis virus Subject Seriola dumerili Remove constraint Subject: Seriola dumerili Subject term Seriola dumerili Remove constraint Subject term: Seriola dumerili Text Availability Citation in PubAg Remove constraint Text Availability: Citation in PubAg
Start Over

Search

1  Search Results

1 entry found
Number of results to display per page

Search Results

1. Antibody profiling using a recombinant protein–based multiplex ELISA array accelerates recombinant vaccine development: Case study on red sea bream iridovirus as a reverse vaccinology model

Author:
Tomomasa Matsuyama; Natsumi Sano; Tomokazu Takano; Takamitsu Sakai; Motoshige Yasuike; Atushi Fujiwara; Yasuhiko Kawato; Jun Kurita; Kazunori Yoshida; Yukinori Shimada; Chihaya Nakayasu
Source:
Vaccine 2018 v.36 no.19 pp. 2643-2649
ISSN:
0264-410X
Subject:
Infectious spleen and kidney necrosis virus; Seriola dumerili; Seriola quinqueradiata; antibodies; antigens; blood serum; case studies; enzyme-linked immunosorbent assay; fish; genes; immune response; models; pathogens; prediction; protective effect; recombinant vaccines; screening; sorbents; vaccine development
Abstract:
... Predicting antigens that would be protective is crucial for the development of recombinant vaccine using genome based vaccine development, also known as reverse vaccinology. High-throughput antigen screening is effective for identifying vaccine target genes, particularly for pathogens for which minimal antigenicity data exist. Using red sea bream iridovirus (RSIV) as a research model, we developed ...
DOI:
10.1016/j.vaccine.2018.03.059